MMJ BioScience Licensed in Canada to Make Cannabis-based Medicine for Huntington’s Studies

MMJ BioScience received a licence from Health Canada to develop cannabis-derived products based on proprietary formulations for the treatment of Huntington’s disease and multiple sclerosis (MS).

The license will enable MMJ to extract active pharmaceutical ingredients from the cannabis plant to manufacture gelcap medications and supply pharmaceutical-grade medicines for its studies which have been approved by the U.S. Food and Drug Administration.

The license includes MMJ 001, a cannabidiol (CBD) derivative for MS, and MMJ-002, a CBD derivative for Huntington’s.

”MMJ is in the process of securing orphan [drug] designation for our lead product, MMJ 001, a cannabidiol (CBD) derivative, for multiple sclerosis in the U.S.,” Tim Moynahan, MMJ BioScience’s chairman, said in a press release.

“MMJ BioScience also plans to repeat that accomplishment for MMJ-102 for Huntington’s disease,” he said.

“The FDA’s granting of orphan designation for multiple sclerosis is a key step toward that goal. These are debilitating diseases that need new

... read more at: https://huntingtonsdiseasenews.com/2018/03/15/mmj-bioscience-licensed-canada-make-cannabis-medicine-huntingtons-studies/

by